SG11202107848TA - Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof - Google Patents

Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof

Info

Publication number
SG11202107848TA
SG11202107848TA SG11202107848TA SG11202107848TA SG11202107848TA SG 11202107848T A SG11202107848T A SG 11202107848TA SG 11202107848T A SG11202107848T A SG 11202107848TA SG 11202107848T A SG11202107848T A SG 11202107848TA SG 11202107848T A SG11202107848T A SG 11202107848TA
Authority
SG
Singapore
Prior art keywords
compound
alkyl
cycloalkyl
group
alkoxy
Prior art date
Application number
SG11202107848TA
Other languages
English (en)
Inventor
Zhonghui Chen
Shuangshuang Duan
Guiying Li
Runfeng Han
Qizheng Sun
Liandong Jing
Xiaojun Han
Qiang Tian
Hongmei Song
Tongtong Xue
Jingyi Wang
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of SG11202107848TA publication Critical patent/SG11202107848TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11202107848TA 2019-02-19 2020-02-11 Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof SG11202107848TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910124584 2019-02-19
CN201910437878 2019-05-24
CN201910932095 2019-09-29
PCT/CN2020/074696 WO2020168939A1 (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
SG11202107848TA true SG11202107848TA (en) 2021-08-30

Family

ID=72143544

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107848TA SG11202107848TA (en) 2019-02-19 2020-02-11 Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof

Country Status (16)

Country Link
US (1) US20220144847A1 (enExample)
EP (1) EP3929198A4 (enExample)
JP (2) JP7615056B2 (enExample)
KR (1) KR102977603B1 (enExample)
CN (3) CN117327078A (enExample)
AU (1) AU2020226422C1 (enExample)
BR (1) BR112021016299A2 (enExample)
CA (1) CA3130245A1 (enExample)
CL (1) CL2021002205A1 (enExample)
CO (1) CO2021011023A2 (enExample)
IL (1) IL285378B2 (enExample)
MX (1) MX2021009971A (enExample)
PH (1) PH12021552004A1 (enExample)
SA (1) SA521430084B1 (enExample)
SG (1) SG11202107848TA (enExample)
WO (1) WO2020168939A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7688690B2 (ja) * 2020-07-28 2025-06-04 スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド ピリミジン系化合物の塩、結晶形およびその調製方法
WO2022199503A1 (zh) 2021-03-24 2022-09-29 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法
CN114235976B (zh) * 2021-11-09 2023-11-03 暨南大学 一种含氮杂环有机化合物中间产物的合成和分析方法
CN120897743A (zh) 2023-05-19 2025-11-04 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与ret基因改变相关疾病的用途和方法
WO2025256440A1 (zh) * 2024-06-14 2025-12-18 四川科伦博泰生物医药股份有限公司 含杂环化合物富马酸盐的制备方法
WO2026017002A1 (zh) * 2024-07-16 2026-01-22 四川科伦博泰生物医药股份有限公司 以杂环化合物为活性成分的药物组合物、其制备方法及用途
GB202410599D0 (en) * 2024-07-19 2024-09-04 Ellipses Pharma Ltd Therapeutics useful synergistic combinations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166734A (zh) * 2005-02-28 2008-04-23 日本烟草产业株式会社 具有Syk抑制活性的新型的氨基吡啶化合物
BRPI0607062A2 (pt) * 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US20080234267A1 (en) * 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
JP2010208945A (ja) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
JP2013107824A (ja) * 2010-03-17 2013-06-06 Dainippon Sumitomo Pharma Co Ltd 新規単環ピリミジン誘導体
WO2012057262A1 (ja) * 2010-10-28 2012-05-03 日本新薬株式会社 ピリジン誘導体及び医薬
WO2012154518A1 (en) * 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
US10202365B2 (en) * 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) * 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物

Also Published As

Publication number Publication date
AU2020226422A1 (en) 2021-09-09
IL285378B1 (en) 2025-07-01
PH12021552004A1 (en) 2022-09-05
NZ778907A (en) 2025-05-30
CN113316578A (zh) 2021-08-27
WO2020168939A1 (zh) 2020-08-27
CO2021011023A2 (es) 2021-09-09
AU2020226422C1 (en) 2026-04-02
JP7615056B2 (ja) 2025-01-16
JP7821259B2 (ja) 2026-02-26
KR20210131314A (ko) 2021-11-02
US20220144847A1 (en) 2022-05-12
IL285378A (en) 2021-09-30
CN117327078A (zh) 2024-01-02
JP2025060928A (ja) 2025-04-10
SA521430084B1 (ar) 2025-05-01
AU2020226422B2 (en) 2025-07-31
CL2021002205A1 (es) 2022-04-22
EP3929198A1 (en) 2021-12-29
BR112021016299A2 (pt) 2021-10-13
CN113316578B (zh) 2023-10-31
JP2022521859A (ja) 2022-04-12
CN117263945A (zh) 2023-12-22
CN117263945B (zh) 2026-08-11
IL285378B2 (en) 2025-11-01
MX2021009971A (es) 2021-10-13
KR102977603B1 (ko) 2026-06-12
CA3130245A1 (en) 2020-08-27
EP3929198A4 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
CN113666911B (zh) Fgfr抑制剂化合物及其用途
ES2985542T3 (es) Compuesto inhibidor de JAK y uso del mismo
CN114591319B (zh) 四氢吡啶并嘧啶类衍生物及其用途
CN109790161B (zh) 具有glp-1受体激动剂作用的吡唑并吡啶衍生物
JP7821259B2 (ja) 複素環化合物、これを含む薬物組成物、その製造方法および使用
JP2023554506A (ja) Fgfr阻害剤化合物及びその使用
CN111712499A (zh) 一种atr抑制剂及其应用
CN112812100B (zh) 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
WO2020186220A1 (en) Compounds as inhibitors of macrophage migration inhibitory factor
CN113993861B (zh) 吡唑基-氨基-嘧啶基衍生物的苯醚和苯胺及其组合物和方法
WO2022135390A1 (zh) 己酮糖激酶抑制剂及其用途
KR20230159367A (ko) 키나아제 약물 내성 돌연변이와 관련된 질병의 치료에있어서의 헤테로사이클릭 화합물의 용도 및 그 방법
CN113896669A (zh) 雌激素受体调节剂及其用途
AU2023379802A1 (en) Mc4r antagonist compound, pharmaceutical composition and pharmaceutical use thereof
WO2022095909A1 (zh) 用作ntrk激酶抑制剂的化合物及其应用
RU2828045C2 (ru) Гетероциклическое соединение, фармацевтическая композиция, содержащая его, способ его получения и его применение
CN115043844B (zh) Trk激酶抑制剂化合物及其用途
HK40051009A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
EA050235B1 (ru) Соединения и их применение в виде ингибиторов gpr183
HK40051009B (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
JP2026502170A (ja) リガンド標的irak3分解剤としての置換イミダゾ系化合物
EA048017B1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
HK40036987A (en) Atr inhibitor and application thereof
BR122024013896A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma